Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
45
MD Quote, Financials, Valuation and Earnings
Last price:
$14.09
Seasonality move
:
-0.34%
Day range:
$14.01 - $14.69
52-week range:
$6.62 - $16.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.59x
P/B ratio:
1.65x
Volume:
4.7M
Avg. volume:
829.3K
1-year change:
57.25%
Market cap:
$1.2B
Revenue:
$2B
EPS (TTM):
-$3.06
Analysts' Opinion
-
Consensus RatingPediatrix Medical Group has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Pediatrix Medical Group has an estimated upside of 15.08% from its current price of $14.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $14.09.
Fair Value
-
According to the consensus of 0 analysts, Pediatrix Medical Group has 15.08% upside to fair value with a price target of -- per share.
MD vs. S&P 500
-
Over the past 5 trading days, Pediatrix Medical Group has overperformed the S&P 500 by 2.17% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pediatrix Medical Group does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pediatrix Medical Group has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Pediatrix Medical Group reported revenues of $511.2M.
Earnings Growth
-
Pediatrix Medical Group earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pediatrix Medical Group reported earnings per share of $0.23.
Enterprise value:
1.6B
EV / Invested capital:
1.19x
Price / LTM sales:
0.59x
EV / EBIT:
--
EV / Revenue:
0.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.03x
Price / Operating cash flow:
10.20x
Enterprise value / EBITDA:
72.88x
Gross Profit (TTM):
$427M
Return On Assets:
-11.77%
Net Income Margin (TTM):
-12.65%
Return On Equity:
-30.86%
Return On Invested Capital:
-17.29%
Operating Margin:
10.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2B | $2B | $2B | $506.6M | $511.2M | |
| Gross Profit | $489.1M | $436.2M | $427M | $106.9M | $116.8M | |
| Operating Income | $215.4M | $174.4M | $164.6M | $40.3M | $52.4M | |
| EBITDA | $187.8M | $196.5M | -$198M | $50.4M | $41.6M | |
| Diluted EPS | $0.99 | $1.13 | -$3.06 | $0.26 | $0.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.7B | $788M | $423.7M | $420.5M | $528.2M | |
| Total Assets | $3.4B | $2.6B | $2.3B | $2.3B | $2.1B | |
| Current Liabilities | $488.4M | $397.6M | $351.7M | $350.4M | $373.1M | |
| Total Liabilities | $2.6B | $1.8B | $1.5B | $1.4B | $1.3B | |
| Total Equity | $805M | $845.7M | $858.7M | $968M | $732.5M | |
| Total Debt | $1.7B | $1B | $745.9M | $636.6M | $626.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $112.5M | $166.8M | $142.8M | $79.9M | $91.8M | |
| Cash From Investing | -$61.3M | -$47M | -$45.9M | -$14M | -$4.3M | |
| Cash From Financing | -$400.4M | -$107.3M | -$14.3M | -$50.6M | -$3.1M | |
| Free Cash Flow | $88.7M | $133.4M | $115.2M | $70.8M | $85.5M | |
MD
Sector
Market Cap
$1.2B
$44.6M
Price % of 52-Week High
85.86%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
0.81%
-0.68%
1-Year Price Total Return
57.26%
-29.09%
Beta (5-Year)
1.570
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$14.18
200-day SMA
Buy
Level
$10.32
Bollinger Bands (100)
Buy
Level
10.31 - 14.43
Chaikin Money Flow
Buy
Level
79.5M
20-day SMA
Sell
Level
$14.53
Relative Strength Index (RSI14)
Sell
Level
45.66
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-74.6154
50-day SMA
Sell
Level
$14.13
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
43.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1881)
Sell
CA Score
(Annual)
Level (-0.6806)
Buy
Beneish M-Score
(Annual)
Level (-2.9245)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (0.043)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.
Stock Forecast FAQ
In the current month, MD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MD average analyst price target in the past 3 months is --.
-
Where Will Pediatrix Medical Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pediatrix Medical Group share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Pediatrix Medical Group?
Analysts are divided on their view about Pediatrix Medical Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pediatrix Medical Group is a Sell and believe this share price will drop from its current level to --.
-
What Is Pediatrix Medical Group's Price Target?
The price target for Pediatrix Medical Group over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pediatrix Medical Group is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MD?
You can purchase shares of Pediatrix Medical Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pediatrix Medical Group shares.
-
What Is The Pediatrix Medical Group Share Price Today?
Pediatrix Medical Group was last trading at $14.09 per share. This represents the most recent stock quote for Pediatrix Medical Group. Yesterday, Pediatrix Medical Group closed at $14.09 per share.
-
How To Buy Pediatrix Medical Group Stock Online?
In order to purchase Pediatrix Medical Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
